P J Clements

Summary

Affiliation: University of California
Country: USA

Publications

  1. doi Arthritis in systemic sclerosis: systematic review of the literature and suggestions for the performance of future clinical trials in systemic sclerosis arthritis
    Philip J Clements
    David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 1670, USA
    Semin Arthritis Rheum 41:801-14. 2012
  2. doi The pulmonary arterial hypertension quality enhancement research initiative: comparison of patients with idiopathic PAH to patients with systemic sclerosis-associated PAH
    Philip J Clements
    Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
    Ann Rheum Dis 71:249-52. 2012
  3. ncbi Assessment of gastrointestinal involvement
    P J Clements
    Division of Rheumatology Medicine, Rm 32 59, 1000 Veteran Avenue, UCLA School of Medicine, Los Angeles, California, USA
    Clin Exp Rheumatol 21:S15-8. 2003
  4. pmc Scleroderma lung study (SLS): differences in the presentation and course of patients with limited versus diffuse systemic sclerosis
    Philip J Clements
    Divisions of Rheumatology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Ann Rheum Dis 66:1641-7. 2007
  5. ncbi Regional differences in bronchoalveolar lavage and thoracic high-resolution computed tomography results in dyspneic patients with systemic sclerosis
    Philip J Clements
    Department of Medicine, University of California, Los Angeles, 90095, USA
    Arthritis Rheum 50:1909-17. 2004
  6. ncbi High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial: lessons learned
    Philip J Clements
    Division of Rheumatology, UCLA School of Medicine, Los Angeles, CA 90095 1670, USA
    Semin Arthritis Rheum 33:249-63. 2004
  7. pmc Differences in presentation of younger and older systemic sclerosis patients in clinical trials
    H H Weng
    Amgen Inc, Thousand Oaks, CA, USA
    Clin Exp Rheumatol 28:S10-4. 2010
  8. ncbi The Disability Index of the Health Assessment Questionnaire is a predictor and correlate of outcome in the high-dose versus low-dose penicillamine in systemic sclerosis trial
    P J Clements
    UCLA School of Medicine, Los Angeles, California 90095-1670, USA
    Arthritis Rheum 44:653-61. 2001
  9. ncbi Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study
    Dinesh Khanna
    David Geffen School of Medicine, University of California, Los Angeles, USA
    Arthritis Rheum 52:592-600. 2005
  10. pmc Course of the modified Rodnan skin thickness score in systemic sclerosis clinical trials: analysis of three large multicenter, double-blind, randomized controlled trials
    Sogol Amjadi
    Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
    Arthritis Rheum 60:2490-8. 2009

Detail Information

Publications44

  1. doi Arthritis in systemic sclerosis: systematic review of the literature and suggestions for the performance of future clinical trials in systemic sclerosis arthritis
    Philip J Clements
    David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 1670, USA
    Semin Arthritis Rheum 41:801-14. 2012
    ....
  2. doi The pulmonary arterial hypertension quality enhancement research initiative: comparison of patients with idiopathic PAH to patients with systemic sclerosis-associated PAH
    Philip J Clements
    Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
    Ann Rheum Dis 71:249-52. 2012
    ....
  3. ncbi Assessment of gastrointestinal involvement
    P J Clements
    Division of Rheumatology Medicine, Rm 32 59, 1000 Veteran Avenue, UCLA School of Medicine, Los Angeles, California, USA
    Clin Exp Rheumatol 21:S15-8. 2003
    ..A minimal core set of variables has been identified to be used in clinical investigation for the assessment of esophagus, stomach, small intestine, colon and anorectum involvement in scleroderma patients...
  4. pmc Scleroderma lung study (SLS): differences in the presentation and course of patients with limited versus diffuse systemic sclerosis
    Philip J Clements
    Divisions of Rheumatology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Ann Rheum Dis 66:1641-7. 2007
    ..This report examines the differences at baseline and over 12 months between patients with limited versus diffuse cutaneous SSc who participated in the Scleroderma Lung Study...
  5. ncbi Regional differences in bronchoalveolar lavage and thoracic high-resolution computed tomography results in dyspneic patients with systemic sclerosis
    Philip J Clements
    Department of Medicine, University of California, Los Angeles, 90095, USA
    Arthritis Rheum 50:1909-17. 2004
    ..This study was undertaken to investigate the utility of high-resolution computed tomography (HRCT) of the chest, in comparison with bronchoalveolar lavage (BAL), in the diagnosis of alveolitis in these patients...
  6. ncbi High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial: lessons learned
    Philip J Clements
    Division of Rheumatology, UCLA School of Medicine, Los Angeles, CA 90095 1670, USA
    Semin Arthritis Rheum 33:249-63. 2004
    ..To review important findings, or lessons, that were learned about measures of response, design, conduct, and analysis of a randomized, controlled trial (RCT), even though the trial failed to demonstrate efficacy of d-penicillamine...
  7. pmc Differences in presentation of younger and older systemic sclerosis patients in clinical trials
    H H Weng
    Amgen Inc, Thousand Oaks, CA, USA
    Clin Exp Rheumatol 28:S10-4. 2010
    ..To compare the characteristics of younger and older subjects with diffuse cutaneous systemic sclerosis (SSc) entering clinical trials...
  8. ncbi The Disability Index of the Health Assessment Questionnaire is a predictor and correlate of outcome in the high-dose versus low-dose penicillamine in systemic sclerosis trial
    P J Clements
    UCLA School of Medicine, Los Angeles, California 90095-1670, USA
    Arthritis Rheum 44:653-61. 2001
    ..The HAQ DI is a self-administered questionnaire that SSc patients can complete easily and rapidly and that gives the practicing physician important information about prognosis, patient status, and changes in disease course over time...
  9. ncbi Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study
    Dinesh Khanna
    David Geffen School of Medicine, University of California, Los Angeles, USA
    Arthritis Rheum 52:592-600. 2005
    ....
  10. pmc Course of the modified Rodnan skin thickness score in systemic sclerosis clinical trials: analysis of three large multicenter, double-blind, randomized controlled trials
    Sogol Amjadi
    Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
    Arthritis Rheum 60:2490-8. 2009
    ....
  11. ncbi Management of interstitial lung disease in systemic sclerosis: lessons from SLS and FAST
    Nihal Fathi
    David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
    Curr Rheumatol Rep 9:144-50. 2007
    ....
  12. pmc Systemic sclerosis and bilateral lung transplantation: a single centre experience
    R Saggar
    Division of Pulmonary and Critical Care Medicine, Dept of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 1690, USA
    Eur Respir J 36:893-900. 2010
    ..AR rates may be significantly higher in the SSc group. Longer follow-up is necessary to determine the effects of gastrointestinal dysfunction and AR on late allograft function in SSc LTR...
  13. ncbi Current concepts in disease-modifying therapy for systemic sclerosis-associated interstitial lung disease: lessons from clinical trials
    Karen Au
    Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine at UCLA, 10833 Le Conte Avenue, Los Angeles, CA 90095, USA
    Curr Rheumatol Rep 11:111-9. 2009
    ..A randomized double-blind controlled trial by the Scleroderma Lung Study Research Group is currently comparing the efficacy and safety of mycophenolate mofetil versus oral cyclophosphamide...
  14. ncbi Measures of response in clinical trials of systemic sclerosis: the Combined Response Index for Systemic Sclerosis (CRISS) and Outcome Measures in Pulmonary Arterial Hypertension related to Systemic Sclerosis (EPOSS)
    Dinesh Khanna
    David Geffen School at University of California, Los Angeles, CA, USA
    J Rheumatol 36:2356-61. 2009
    ..CRISS and EPOSS are being developed through the OMERACT process. Through Delphi process and literature review significant progress has been made for both indices, and prospective data are being collected...
  15. pmc Minimally important difference in diffuse systemic sclerosis: results from the D-penicillamine study
    D Khanna
    Division of Immunology, Department of Medicine, University of Cincinnati, ML 0563, Cincinnati, OH 45267 0563, USA
    Ann Rheum Dis 65:1325-9. 2006
    ..To estimate minimally important differences (MIDs) in scores for the modified Rodnan Skin Score (mRSS) and Health Assessment Questionnaire-Disability Index (HAQ-DI) in a clinical trial on diffuse systemic sclerosis (SSc)...
  16. pmc Minimally important differences in the Mahler's Transition Dyspnoea Index in a large randomized controlled trial--results from the Scleroderma Lung Study
    Dinesh Khanna
    Department of Medicine, Division of Rheumatology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA 90095, USA
    Rheumatology (Oxford) 48:1537-40. 2009
    ..Our objective was to assess minimally important difference (MID) for Mahler's Transition Dyspnoea Index (TDI) in SLS...
  17. pmc Reliability and validity of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument
    Dinesh Khanna
    University of California, Los Angeles, CA, USA
    Arthritis Rheum 61:1257-63. 2009
    ..To refine the previously developed scleroderma (systemic sclerosis [SSc]) gastrointestinal tract (GIT) instrument (SSC-GIT 1.0)...
  18. pmc Sensitivity to change of the modified Rodnan skin score in diffuse systemic sclerosis--assessment of individual body sites in two large randomized controlled trials
    Marian Kaldas
    UCLA Olive View, Sylmar, CA, USA
    Rheumatology (Oxford) 48:1143-6. 2009
    ..Our objective was to evaluate the sensitivity of change over time of individual body sites used in the calculation of total MRSS...
  19. pmc Tendon friction rubs in early diffuse systemic sclerosis: prevalence, characteristics and longitudinal changes in a randomized controlled trial
    Puja P Khanna
    Department of Medicine, Division of Rheumatology, David Geffen School of Medicine, UCLA, Los Angeles, CA 90095, USA
    Rheumatology (Oxford) 49:955-9. 2010
    ....
  20. pmc Infliximab may be effective in the treatment of steroid-resistant eosinophilic fasciitis: report of three cases
    Dinesh Khanna
    David Geffen School of Medicine at UCLA, 1000 Veteran Avenue, Room 32 59 Rehabilitation Building, Los Angeles, CA 90095, USA
    Rheumatology (Oxford) 49:1184-8. 2010
    ..EF is a rare fibrosing disorder that may involve skin and internal organs. Current therapies include moderate- to high-dose glucocorticoids with or without use of immunosuppressives...
  21. pmc Association of gastrointestinal involvement and depressive symptoms in patients with systemic sclerosis
    Vijay Bodukam
    Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
    Rheumatology (Oxford) 50:330-4. 2011
    ..0 instrument; and (ii) to explore which GI-specific symptom scales are associated with depressed mood in patients with SSc...
  22. doi High-resolution CT scan findings in patients with symptomatic scleroderma-related interstitial lung disease
    Jonathan G Goldin
    David Geffen School of Medicine at UCLA, Department of Radiology, Los Angeles, CA 90095 1721, USA
    Chest 134:358-67. 2008
    ..The frequency, nature, and progression of interstitial lung disease seen on high-resolution CT (HRCT) scans in patients with diffuse SSc (dcSSc) compared with those with limited SSc (lcSSc) has not been well characterized...
  23. doi Oral cyclophosphamide for active scleroderma lung disease: a decision analysis
    Dinesh Khanna
    Division of Rheumatology, School of Public Health, University of California at Los Angeles, Los Angeles, CA 90095, USA
    Med Decis Making 28:926-37. 2008
    ..Also, the long-term balance of risk and benefit remains unclear...
  24. ncbi Does incorporation of aids and devices make a difference in the score of the health assessment questionnaire-disability index? Analysis from a scleroderma clinical trial
    Dinesh Khanna
    Division of Rheumatology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California, USA
    J Rheumatol 35:466-8. 2008
    ..We assessed if HAQ-DI scores are different when calculated with and without aids/devices, and if apparent responsiveness changes when scored in these 2 ways...
  25. ncbi Systemic sclerosis-associated interstitial lung disease-proposed recommendations for future randomized clinical trials
    Dinesh Khanna
    Division of Rheumatology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
    Clin Exp Rheumatol 28:S55-62. 2010
    ..Recent investigations into the pathogenesis of SSc-ILD have led to a renewed interest in assessing targeted therapies in SSc-ILD. With this in mind, we propose recommendations for the design of future SSc-ILD studies in this review...
  26. pmc Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease
    Donald P Tashkin
    Department of Medicine, David Geffen School of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California 90095 1690, USA
    Am J Respir Crit Care Med 176:1026-34. 2007
    ..Although treatment-related benefits in pulmonary function, skin scores, and patient-centered outcomes were demonstrated after 1 year of therapy, the duration of benefit beyond 1 year was unclear...
  27. ncbi Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial
    Dinesh Khanna
    Division of Rheumatology, Department of Medicine, David Geffen School of Medicine, Los Angeles, California, USA
    J Rheumatol 32:832-40. 2005
    ....
  28. pmc Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trial
    Dinesh Khanna
    David Geffen School of Medicine, and School of Public Health, University of California, Los Angeles, USA
    Arthritis Rheum 60:1102-11. 2009
    ....
  29. ncbi Assessing disease progression using a composite endpoint
    Weng Kee Wong
    Department of Biostatistics, University of California at Los Angeles, CA, USA
    Stat Methods Med Res 16:31-49. 2007
    ..In addition, we propose desirability functions to monitor patients' disease improvement when the outcomes are all continuous. This method offers several possible advantages over existing methods for measuring patients' improvement...
  30. ncbi Cyclophosphamide versus placebo in scleroderma lung disease
    Donald P Tashkin
    University of California at Los Angeles, Los Angeles, USA
    N Engl J Med 354:2655-66. 2006
    ....
  31. pmc Development of a provisional core set of response measures for clinical trials of systemic sclerosis
    D Khanna
    Division of Rheumatology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, California 90095, USA
    Ann Rheum Dis 67:703-9. 2008
    ..To develop a provisional core set of response measures for clinical trials of systemic sclerosis (SSc)...
  32. pmc Rapamycin versus methotrexate in early diffuse systemic sclerosis: results from a randomized, single-blind pilot study
    Tien I Karleen Su
    University of Southern California, Los Angeles, CA 90095 1670, USA
    Arthritis Rheum 60:3821-30. 2009
    ..To assess the safety and efficacy of rapamycin in the treatment of diffuse systemic sclerosis (SSc; scleroderma)...
  33. pmc A computer-aided diagnosis system for quantitative scoring of extent of lung fibrosis in scleroderma patients
    H G Kim
    Department of Radiological Sciences, David Geffen School of Medicine, UCLA, Los Angeles, CA 90024 2926, USA
    Clin Exp Rheumatol 28:S26-35. 2010
    ....
  34. ncbi A longitudinal analysis of humor coping and quality of life in systemic sclerosis
    Erin L Merz
    SDSU UCSD Joint Doctoral Program in Clinical Psychology, San Diego, California, USA
    Psychol Health Med 14:553-66. 2009
    ....
  35. ncbi Update on disease-modifying antirheumatic drugs in the treatment of systemic sclerosis
    Antony T H Lin
    Division of Rheumatology, Department of Medicine, University of California at Los Angeles, Los Angeles, CA 90095, USA
    Rheum Dis Clin North Am 29:409-26. 2003
    ....
  36. ncbi New onset systemic lupus erythematosus with pheochromocytoma
    Antony T H Lin
    Department of Medicine, UCLA School of Medicine, USA
    J Rheumatol 29:1334-7. 2002
    ..This is a novel case of pheochromocytoma discovered at the onset of SLE, with resolution of SLE manifestations shortly after its removal...
  37. ncbi Lymphomatoid granulomatosis: a rare mimicker of vasculitis
    Sherry M Wu
    Division of Rheumatology, Olive View UCLA Medical Center, David Geffen School of Medicine, Los Angeles, CA 91342, USA
    J Rheumatol 32:2242-5. 2005
    ..We describe a case of LG with no pulmonary involvement, which was thought to be systemic vasculitis on the basis of multiorgan involvement and biopsy findings...
  38. ncbi Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung study
    Dinesh Khanna
    University of Cincinnati, Cincinnati, Ohio 45267 0563, USA
    Arthritis Rheum 56:1676-84. 2007
    ..To assess the impact of cyclophosphamide (CYC) on the health-related quality of life (HRQOL) of patients with scleroderma after 12 months of treatment...
  39. ncbi Medical signs and symptoms associated with disability, pain, and psychosocial adjustment in systemic sclerosis
    Vanessa L Malcarne
    Department of Psychology, San Diego State University, CA 92120 4913, USA
    J Rheumatol 34:359-67. 2007
    ..To examine physician-assessed medical signs and patient-reported medical symptoms as correlates of 3 quality of life (QOL) outcomes in patients with systemic sclerosis (SSc): disability, pain, and psychosocial adjustment...
  40. ncbi Single-factor scoring validation for the Health Assessment Questionnaire-Disability Index (HAQ-DI) in patients with systemic sclerosis and comparison with early rheumatoid arthritis patients
    Jason C Cole
    Consulting Measurement Group, Huntington Beach, CA 91403, USA
    Qual Life Res 15:1383-94. 2006
    ..The goal of the current study was to examine the structural validity of the HAQ-DI in patients with systemic sclerosis (SSc, scleroderma) and to compare its performance with that in patients with RA...
  41. ncbi Current status of outcome measure development for clinical trials in systemic sclerosis. Report from OMERACT 6
    Peter A Merkel
    Arthritis Center, Section of Rheumatology, Boston University School of Medicine, Boston, MA 02118, USA
    J Rheumatol 30:1630-47. 2003
    ..The current level of validation of outcome measures in SSc is assessed according to the guidelines set forth by prior OMERACT meetings...
  42. ncbi Development of a preliminary scleroderma gastrointestinal tract 1.0 quality of life instrument
    Dinesh Khanna
    University of Cincinnati, The Veterans Affairs Medical Center, Cincinnati, Ohio, USA
    Arthritis Rheum 57:1280-6. 2007
    ..Gastrointestinal tract (GIT) involvement occurs in approximately 90% of patients with systemic sclerosis (SSc) and has a major impact on health-related quality of life (HRQOL). We developed an HRQOL instrument for persons with SSc...
  43. ncbi Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial
    Paul J DeMarco
    Marshfield Clinic, Wausau, Wisconsin, USA
    Arthritis Rheum 46:2983-9. 2002
    ..Early use of angiotensin-converting enzyme (ACE) inhibitors has markedly improved outcome. The present analysis reexamines the prognostic factors for and outcome of SRC in a prospective cohort of patients with early diffuse SSc...
  44. ncbi Reliability, validity, and minimally important differences of the SF-6D in systemic sclerosis
    Dinesh Khanna
    Division of Immunology, Department of Internal Medicine, University of Cincinnati Medical Center, PO Box 670563, Cincinnati, OH 45267 0563, USA
    Qual Life Res 16:1083-92. 2007
    ....